Advertisement

Topics

Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

2014-08-27 03:56:48 | BioPortfolio

Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of radiolabeled monoclonal antibody when given together with pentetic acid calcium and to see how well they work in treating patients with recurrent Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Description

OBJECTIVES:

- Assess the toxicity and therapeutic efficacy of yttrium Y 90 radiolabeled humanized anti-Tac (HAT) monoclonal antibody in patients with Tac expressing hematologic malignancies.

- Define the pharmacokinetics of indium In 111 and yttrium Y 90 HAT monoclonal antibodies.

OUTLINE: This is a dose-escalation study.

Patients are given yttrium Y 90 labeled humanized anti-Tac monoclonal antibody (Y-HAT) according to an escalating dose schedule along with a fixed dose of pentetic acid calcium (Ca-DTPA) and indium In 111 labeled humanized anti-Tac monoclonal antibody (In-HAT). On day 1, Y-HAT and In-HAT are administered IV over 2 hours followed by a 5-hour infusion of Ca-DTPA. Additional 5-hour infusions of Ca-DTPA are given on days 2 and 3. Treatment may repeat every 6 weeks for up to 7 courses.

Cohorts of 3 to 6 patients are enrolled at each dose level. Dose escalation continues until the maximum-tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more patients experience dose-limiting toxicity. After the MTD is defined the phase II portion of the study begins.

PROJECTED ACCRUAL: Approximately 65 patients will be accrued in phase I and an additional 30 patients in phase II.

Study Design

Primary Purpose: Treatment

Conditions

Lymphoma

Intervention

daclizumab, pentetic acid calcium

Location

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda
Maryland
United States
20892-1182

Status

Recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:56:48-0400

Clinical Trials [3012 Associated Clinical Trials listed on BioPortfolio]

Monoclonal Antibody Therapy in Treating Patients With Leukemia

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study t...

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma

Background: - Hodgkin s lymphoma (HL) is a highly treatable cancer. However, if HL does not respond to chemotherapy or returns after chemotherapy, further treatments often are n...

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab...

Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss

Primary Objective: - Evaluate the effect of zoledronate on change in BMD at the total lumbar spine and femoral neck. Secondary Objectives: - Evaluate the effect o...

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

This protocol is designed to obtain information on the drug levels, metabolism, and safety of daclizumab (Zenapax(R)) in children and adolescents undergoing cardiac transplantation. In add...

PubMed Articles [9199 Associated PubMed Articles listed on BioPortfolio]

Neurotrophic Action of Comenic Acid and Its Derivatives Potassium Comenate and Calcium Comenate.

Using the model of cultured spinal ganglia, we demonstrated high neurotrophic activity of comenic acid and its derivatives potassium comenate and calcium comenate both under normal conditions and duri...

Impact of Potassium Citrate vs. Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.

No medication has been shown to be effective at preventing recurrence of calcium phosphate urinary stones. Potassium citrate may protect against calcium phosphate stones by enhancing urine citrate exc...

Effect of exogenous calcium on growth, nutrients uptake and plasma membrane H-ATPase and Ca-ATPase activities in soybean (Glycine max) seedlings under simulated acid rain stress.

Calcium (Ca) is one of essential elements for plant growth and development, and also plays a role in regulating plant cell physiology and cellular response to the environment. Here, we studied whether...

Application of Calcium Silicate Materials After Acid Etching May Preserve Resin-Dentin Bonds.

The aim of the present study was to evaluate the effect of the application of calcium silicate materials (CSMs), after acid etching, on the longevity of the hybrid layer and marginal adaptation of com...

Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods.

We compared two methods of calcium gluconate infusion to maintain plasma ionized calcium ([Ca ]) during therapeutic plasma exchange (TPE) performed using the Spectra Optia Apheresis System. Method A, ...

Medical and Biotech [MESH] Definitions

An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.

A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)

Calcium salts of phosphoric acid. These compounds are frequently used as calcium supplements.

The calcium salt of gluconic acid. The compound has a variety of uses, including its use as a calcium replenisher in hypocalcemic states.

Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.

More From BioPortfolio on "Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial